Nemes Rush Group’s SELLAS Life Sciences SLS Stock Holding History

Nemes Rush Group’s Portfolio SLS Stock Details SLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$42.3K	Hold	10,000	–	–	﹤0.01%	381
2025 Q4	$37.7K	Hold	10,000	–	–	﹤0.01%	377
2025 Q3	$16.1K	Hold	10,000	–	–	﹤0.01%	442
2025 Q2	$21.9K	Hold	10,000	–	–	﹤0.01%	411
2025 Q1	$10.8K	Hold	10,000	–	–	﹤0.01%	459
2024 Q4	$10.4K	Hold	10,000	–	–	﹤0.01%	460
2024 Q3	$10.1K	Hold	10,000	–	–	﹤0.01%	400
2024 Q2	$11.9K	Hold	10,000	–	–	﹤0.01%	392
2024 Q1	$10.1K	Hold	10,000	–	–	﹤0.01%	435
2023 Q4	$10.6K	Hold	10,000	–	–	﹤0.01%	421
2023 Q3	$16.4K	Hold	10,000	–	–	﹤0.01%	356
2023 Q2	$15.7K	Buy	+10,000	New	+$16.1K	﹤0.01%	382

Other funds holding SLS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Nemes Rush Group's SLS Position: Q1 2026 in Review

Nemes Rush Group held its SELLAS Life Sciences (SLS) position steady in Q1 2026 at 10,000 shares worth $42.3K. The position accounts for ﹤0.01% of the portfolio, ranked #381.

Nemes Rush Group first reported a position in SLS in Q2 2023 and has held it in 12 quarters since. 160 funds tracked by Wall St. Rank hold SLS as of Q1 2026.

Nemes Rush Group held 10,000 shares of SELLAS Life Sciences worth $42.3K as of Q1 2026.
Nemes Rush Group left its SELLAS Life Sciences share count unchanged in Q1 2026.
SELLAS Life Sciences made up ﹤0.01% of Nemes Rush Group's portfolio in Q1 2026, its #381 holding.
Nemes Rush Group first reported a position in SELLAS Life Sciences in Q2 2023 and has held it in 12 quarters since.
160 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q1 2026.

Based on Nemes Rush Group's 13F filing for Q1 2026, filed 21 Apr 2026.